Skip to content

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy

Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04746729
Acronym
HARMONIC-RT
Enrollment
2670
Registered
2021-02-10
Start date
2021-01-11
Completion date
2042-01-02
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Keywords

Radiotherapy, Oncology, Paediatrics, Late toxicities, Radiation-induced neoplasms, Radiation-induced vascular damages, Radiation-induced cardiac damages, Radiation-induced endocrine damages, Quality of life, Social outcomes, External beam radiotherapy, Photon therapy, Proton therapy, Cohort, Registry

Brief summary

The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of contemporary techniques of external beam radiotherapy in paediatric patients, based on the setting-up of a European, long-term registry complemented by a biobank.

Detailed description

Specific objectives: * To develop the infrastructure and instruments for setting-up a European, long-term registry of paediatric patients treated with contemporary techniques of modern external radiotherapy; * To assess the incidence and severity of late health outcomes, primarily endocrine dysfunctions, cardiovascular toxicities, neurovascular damages, and subsequent primary neoplasms, in relation to the dose-volume distribution to non-targeted organs and tissues, radiation delivery technique and beam quality factors, and potential modifying factors (i.e. age at exposure, genetic predispositions, comorbidities, and systemic treatments including chemotherapy, targeted therapy, immunotherapy and hormonal drugs) that may underlie differences in individual susceptibility for these outcomes ; * To assess societal aspects of advances in radiotherapy, primarily health-related quality of life and academic achievement, in paediatric patients treated with modern external radiotherapy techniques. Secondary scientific objectives: * To assess multidimensional fatigue in paediatric patients treated with modern external radiotherapy techniques, and identify clinical and therapeutic determinants of fatigue; * To improve estimation of patient-specific doses to the whole body and non-targeted organs and substructures from different radiotherapy delivery techniques; * To investigate radiation-induced cellular responses and biological mechanisms related to the occurrence of vascular diseases and subsequent primary neoplasms in samples of blood and saliva ; to identify biomarkers of susceptibility and health effects ; to evaluate differences in disease biomarkers in relation to the radiation delivery technique and beam quality factors ; to explore the relevance of the use of saliva as a biosampling method for paediatric cohorts regarding feasibility and the quality and reproducibility for different measured biomarkers. Secondary strategic objectives: * To promote sustained collaborative research activities for improvement of patient care, and inform health care providers and policy makers on the clinical and social impact of advances in radiotherapy in paediatric settings; * To serve as a pilot for a future long-term pan-European registry of children and adolescents treated with particle and photon beam therapy, including a biobank of saliva and blood samples collected before and after treatment; * To contribute in future collaborative projects with existing cohorts or registries in Europe * To contribute in future international research studies on late outcomes of modern radiotherapy techniques for management of paediatric cancers Funding: The HARMONIC project has received funding from the Euratom research and training programme 2014-2018 under grant agreement No 847707.

Interventions

OTHERNo intervention

No intervention

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV
Barcelona Institute for Global Health
CollaboratorOTHER
The West German Proton Therapy Centre, Essen
CollaboratorUNKNOWN
Gustave Roussy, Cancer Campus, Grand Paris
CollaboratorOTHER
Centre Francois Baclesse
CollaboratorOTHER
KU Leuven
CollaboratorOTHER
University of Aarhus
CollaboratorOTHER
Princess Maxima Center for Pediatric Oncology
CollaboratorOTHER
University Medical Center Groningen
CollaboratorOTHER
Stockholm University
CollaboratorOTHER
National Research Council, Institute of Clinical Physiology, Italy
CollaboratorOTHER
University of Zurich
CollaboratorOTHER
Commissariat A L'energie Atomique
CollaboratorOTHER_GOV
Luxembourg Institute of Science and Technology
CollaboratorOTHER
University Hospital, Essen
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 22 Years
Healthy volunteers
No

Inclusion criteria

Retrospective inclusion of study participants Inclusion Criteria: * First external beam radiation therapy (EBRT) started in 2000 or after for management of a first primary neoplasm * Age under 22 years at the time of first EBRT initiation * Radiation treatment plan (first EBRT) stored in DICOM format * Usual residency in the country of EBRT to enable a long-term follow-up

Exclusion criteria

* Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma) at first EBRT initiation * Prior external or internal radiation therapy * Patients who refused to participate in the study Prospective inclusion of study participants Inclusion Criteria: * Scheduled first EBRT for management of a first primary neoplasm * Age under 22 years at the time of scheduled first EBRT * Radiation treatment plan stored in DICOM format * Affiliate or beneficiary of health insurance (or any required equivalent as defined in applicable national law) * Usual residency in the country of EBRT to enable a long-term follow-up * Signed informed consent/assent

Design outcomes

Primary

MeasureTime frameDescription
Endocrinopathiesup to 20 years after RTLate health outcomes
Cardiovascular diseasesup to 20 years after RTLate health outcomes * Neurovascular diseases * Second and subsequent primary neaoplasms
Neurovascular diseasesup to 20 years after RTLate health outcomes
Second and subsequent primary neaoplasmsup to 20 years after RTLate health outcomes
Health-related quality of life (physical, emotional, social, and school functioning) assessed by the PedsQL™ core scale (validated questionnaire)up to 10 years after radiation therapy or attained age 25 years, whichever occurs firstLate social outcomes
Academic achievementup to 10 years after radiation therapy or attained age 25 years, whichever occurs firstLate social outcomes

Secondary

MeasureTime frameDescription
Dysfunctions in endocrine hormone levelsup to 10 years after radiation therapymeasured as: 1. insulin-like growth factor-1, 2. anterior pituitary hormones (GH, ACTH, TSH, LH, FSH), 3. thyroid hormones (fT3, fT4), 4. sexual hormones
Changes in blood markers of cardiovascular diseasesup to 10 years after radiation therapymeasured as blood markers (incl. troponin, BNP, CPK)
Changes in imaging markers of cardiovascular diseasesup to 10 years after radiation therapymeasured as cardiac echography parameters (incl. ejection fraction, diastolic function)
Changes in imaging markers of neurovascular damagesup to 5 years after radiation therapymeasured as scoring of large and small vessel damages
Changes in blood/saliva markers of protein activation relating to vascular damagesup to 1 year after radiation therapymeasured as signal quality of protein activity
Changes in blood/saliva markers of oxidative stress responseup to 1 year after radiation therapymeasured as markers of oxidative stress (incl. 8-oxo-dG, SOD2, DNA repair enzymes)
Changes in blood/saliva markers of inflammatory responseup to 1 year after radiation therapyInflammatory markers (incl. PTX3, CRP, NF-kB, IL-1 and IL10)
Changes in blood/saliva markers of carcinogenesisup to 1 year after radiation therapyMarkers of carcinogenesis (incl. leukocyte telomere length, mitochondrial DNA copy number, circulating microRNA)
Multidimensional fatigue (general, sleep/rest, and cognitive fatigue)up to 10 years after radiation therapy or attained age 25 years, whichever occurs firstPedsQL™ multidimensional fatigue scale (validated questionnaire)
Clinical events other than those mentioned as primary outcomesup to 20 years after radiation therapyLate morbidity
All-cause and cause-specific mortalityup to 20 years after radiation therapyLate mortality

Countries

Belgium, Denmark, France, Germany

Contacts

CONTACTNeige Journy, PhD
neige.journy@gustaveroussy.fr+33 142 11 54 27
CONTACTBeate Timmermann, MD
beate.timmermann@uk-essen.de+49 201 723 64
PRINCIPAL_INVESTIGATORBeate Timmermann, MD

UK Essen

PRINCIPAL_INVESTIGATORNeige Journy, PhD

Institut National de la Santé Et de la Recherche Médicale, France

PRINCIPAL_INVESTIGATORStéphanie Bolle, MD

Gustave Roussy, Cancer Campus, Grand Paris

STUDY_CHAIRIsabelle Thierry-chef, PhD

Barcelona Institute for Global Health

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026